| Bjelic-Radisic, Vesna |
| Recruiting | 3 | 1260 | Europe | Abemaciclib 50 MG; 150mg 1-0-1 per os, Verzenios | West German Study Group, Eli Lilly and Company, Genomic Health®, Inc. | Breast Cancer Female | 08/26 | 03/28 | | |
| Active, not recruiting | 3 | 1332 | Europe | Capecitabine, Xeloda, Carboplatin, Paraplatin, Cisplatin, Platinol, Sacituzumab govitecan, Trodelvy | German Breast Group, Gilead Sciences, Austrian Breast & Colorectal Cancer Study Group, Spanish Breast Cancer Research Group (GEICAM), ETOP IBCSG Partners Foundation, Cancer Trials Ireland, UNICANCER | HER2-negative Breast Cancer, Triple Negative Breast Cancer | 03/27 | 03/29 | | |
ADAPTcycle, NCT04055493: Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC |
|
|
| Active, not recruiting | 3 | 1684 | Europe | Ribociclib 200Mg Oral Tablet, Kisqali | West German Study Group, Novartis, Genomic Health®, Inc. | Breast Cancer Female | 07/27 | 07/27 | | |
| Recruiting | 3 | 220 | Europe | Elacestrant, Tamoxifen, Letrozole 2.5mg, Anastrozole 1mg, Exemestane 25 MG | European Organisation for Research and Treatment of Cancer - EORTC, Breast International Group, Menarini Group | ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer | 07/28 | 05/30 | | |
PREcoopERA, NCT05896566: A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer |
|
|
| Recruiting | 2 | 220 | Europe | Giredestrant, Triptorelin, Anastrozole | ETOP IBCSG Partners Foundation, Hoffmann-La Roche | Breast Cancer | 06/26 | 06/26 | | |
ADAPTHER2-IV, NCT05704829: NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer |
|
|
| Recruiting | 2 | 402 | Europe | Trastuzumab deruxtecan, ENHERTU, Standard-of-Care, Chemotherapy+T+P | West German Study Group, AstraZeneca | HER2-positive Early Breast Cancer | 06/26 | 06/28 | | |
| Recruiting | N/A | 1470 | Europe | | West German Study Group, Agendia | Female Breast Cancer | 03/35 | 06/35 | | |
| Wermke, Martin |
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy |
|
|
| Active, not recruiting | 3 | 151 | Europe, US, RoW | Pyrotinib, Irene, Docetaxel, Docetaxel injection | Jiangsu HengRui Medicine Co., Ltd. | Non-squamous NSCLC, HER2 Exon 20 Mutation | 06/23 | 10/23 | | |
COSTAR Lung, NCT04655976 / 2020-003433-37: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy |
|
|
| Active, not recruiting | 3 | 758 | Europe, Canada, Japan, US, RoW | Cobolimab, Dostarlimab, Docetaxel | GlaxoSmithKline | Lung Cancer, Non-Small Cell | 04/25 | 10/25 | | |
| Terminated | 2a | 61 | Europe, US, RoW | DRP-104, atezolizumab | Dracen Pharmaceuticals, Inc., Dracen Pharmaceuticals, Inc. | Advanced Solid Tumor, Non Small Cell Lung Cancer Metastatic | 03/23 | 03/23 | | |
| Active, not recruiting | 2 | 168 | Europe, RoW | MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab | Miltenyi Biomedicine GmbH, ICON plc | Diffuse Large B-cell Lymphoma | 12/24 | 07/29 | | |
| Recruiting | 2 | 340 | Europe, Japan, US, RoW | Pembrolizumab, Dostarlimab, GSK4057190, Belrestotug, EOS884448, GSK4428859A, Nelistotug, GSK6097608 | GlaxoSmithKline, iTeos Therapeutics | Lung Cancer, Non-Small Cell | 10/25 | 10/28 | | |
| Active, not recruiting | 2 | 67 | Europe | Atezolizumab | Technische Universität Dresden, Roche Pharma AG | Large Cell Neuroendocrine Carcinoma of the Lung | 01/28 | 01/29 | | |
| Recruiting | 1/2 | 150 | Europe, US | IV ICT01 | ImCheck Therapeutics, ImCheck Therapeutics, Inc. | Solid Tumor, Adult, Hematopoietic/Lymphoid Cancer | 06/25 | 12/25 | | |
|
IMAG1NE, NCT05430555: A Phase 1/ 2, First-in-Human, Open-Label, Accelerated-Titration, Two-Part Clinical Trial of TK-8001 in Patients With HLA-A*02:01 Genotype and Advanced-Stage/ Metastatic MAGE-A1+ Solid Tumors |
|
|
| Terminated | 1/2 | 23 | Europe | Autologous CD8+ T-cells, transduced with MAGE-A1 directed TCR | T-knife GmbH | Advanced Solid Tumors | 01/24 | 01/24 | | |
| Recruiting | 1/2 | 171 | Europe, US, RoW | STX-241 | Pierre Fabre Medicament | Non-small Cell Lung Cancer (NSCLC) | 11/27 | 07/30 | | |
| Recruiting | 1/2 | 500 | Europe, Canada, Japan, US, RoW | Oral repotrectinib (TPX-0005), repotrectinib | Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd. | Locally Advanced Solid Tumors, Metastatic Solid Tumors | 02/28 | 02/28 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NCT03927573: Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker |
|
|
| Terminated | 1 | 23 | Europe | GEM3PSCA | AvenCell Europe GmbH, GCP-Service International Ltd. & Co. KG | Non-small Cell Lung Cancer, Prostate Cancer, Renal Cancer, Transitional Cell Carcinoma | 06/23 | 06/23 | | |
NCT06586515: A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors |
|
|
| Recruiting | 1 | 530 | Europe, Canada, Japan, US | LY3962673, Cetuximab, Gemcitabine, nab-paclitaxel, Oxaliplatin, leucovorin, Irinotecan, 5-fluorouracil | Eli Lilly and Company, Loxo Oncology, Inc. | Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer | 03/29 | 03/29 | | |
NCT04633148: Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker |
|
|
| Terminated | 1 | 16 | Europe | Cyclophosphamide (Non-IMP), Fludarabine (Non-IMP), UniCAR02-T-pPSMA, UniCAR02-T (IMP) | AvenCell Europe GmbH, PHARMALOG Institut für klinische Forschung GmbH | Prostate Cancer | 03/24 | 03/24 | | |
NCT04230265: Dose-escalating Trial With UniCAR02-T Cells and CD123 Target Module (TM123) in Patients With Hematologic and Lymphatic Malignancies |
|
|
| Recruiting | 1 | 90 | Europe | Cyclophosphamide (Non-IMP), Fludarabine (Non-IMP), TM123 (IMP), UniCAR02-T (IMP) | AvenCell Europe GmbH, PHARMALOG Institut für klinische Forschung GmbH | Acute Myeloid Leukemia (AML) | 05/25 | 09/25 | | |
NCT05949125: Dose-escalating Trial With Allo-RevCAR01-T Cells in Combination With CD123 Target Module (R-TM123) for Participants With Selected Hematologic Malignancies Positive for CD123 |
|
|
| Recruiting | 1 | 37 | Europe | Cyclophosphamide (Non-IMP, Lymphodepletion), Fludarabine (Non-IMP, Lymphodepletion), R-TM123, R-TM123 is one component of the Allo-RevCAR01-T-CD123 treatment, Allo-RevCAR01-T, Allo-RevCAR01-T is one component of the Allo-RevCAR01-T-CD123 treatment | AvenCell Europe GmbH, Allucent (NL) BV | Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | 12/25 | 06/26 | | |
| Recruiting | 1 | 476 | Europe, US | IMA203 Product, IMA203 product- flat dose, IMA203CD8 Product, nivolumab (Opdivo®), Opdivo®, IMADetect® | Immatics US, Inc., Immatics US Inc | Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult, Cancer | 12/28 | 12/28 | | |
|
|
DigiNet, NCT05818449: Improvement of Personalized Lung Cancer Care Through Digital Connection and Patient Participation |
|
|
| Active, not recruiting | N/A | 850 | Europe | DigiNet intervention | University of Cologne, Gemeinsamer Bundesausschuss (G-BA), AOK Rheinland/Hamburg, AOK Nordwest, BARMER, University Hospital, Essen, Charite University, Berlin, Germany, Berlin Institute of Health, Helios Klinikum Emil von Behring, University Hospital Carl Gustav Carus, Deutsche Krebsgesellschaft e.V., Berufsverband der Niedergelassenen Hämatologen und Onkologen in Deutschland e.V., AOK Bundesverband, FOM Hochschule für Oekonomie und Management, University Medicine Greifswald, Technische Universität Dresden | Non-small Cell Lung Cancer Stage IV | 03/25 | 03/25 | | |
| Koumarianou, Anna |
GALAXIES Lung-301, NCT06472076: A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, Japan, RoW | Dostarlimab, Belrestotug, Pembrolizumab, Placebo | GlaxoSmithKline, iTeos Therapeutics | Lung Cancer, Non-Small Cell | 09/28 | 09/29 | | |
| Active, not recruiting | 3 | 654 | Europe, Canada, Japan, US, RoW | Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo | Seagen Inc., Merck Sharp & Dohme LLC | HER2 Positive Breast Cancer | 05/25 | 10/27 | | |
|
KROCUS, NCT05756153: A Study of GFH925 in Combination with Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation |
|
|
| Recruiting | 1/2 | 45 | Europe | GFH925, Cetuximab | Genfleet Therapeutics (Shanghai) Inc. | Advance Non-small Cell Lung Cancer | 03/25 | 08/25 | | |
NCT04064359: Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors |
|
|
| Recruiting | 1 | 200 | Europe, US | OBT076, a CD205-directed antibody-drug conjugate, MEN1309 | Oxford BioTherapeutics Ltd | Solid Tumor | 12/26 | 12/27 | | |
| Schlegel, Tina |
IMAG1NE, NCT05430555: A Phase 1/ 2, First-in-Human, Open-Label, Accelerated-Titration, Two-Part Clinical Trial of TK-8001 in Patients With HLA-A*02:01 Genotype and Advanced-Stage/ Metastatic MAGE-A1+ Solid Tumors |
|
|
| Terminated | 1/2 | 23 | Europe | Autologous CD8+ T-cells, transduced with MAGE-A1 directed TCR | T-knife GmbH | Advanced Solid Tumors | 01/24 | 01/24 | | |
| Knöfler, R |
| No trials found |
| Winberger, Pauline |
| No trials found |
